In the lowest dose group.

In the lowest dose group, developed two patients, the treatment is completed completed a T - cell response against hepatitis C at the preliminary result of this first patient to treatment in the medium dose, the first to show a significant reduction in viral load. serious adverse events. The benefits that we hope would see from a successful hepatitis C virus DNA a dramatic reduction in a dramatic reduction in viral load, stated Avtar Dhillon, Inovio's president and CEO. We look forward to the longer-term results of this DNA vaccine and its potential to address this multi-billion dollar market. .

If the patient is completely virus-free six months after completion of treatment, he / she will be considered cured.

This press release contains certain forward-looking statements relating to our plans electroporation electroporation drug and gene delivery technology. Actual events or results may differ materially from our expectations due to a number of factors, including uncertainties in clinical trials and product development programs availability of funds for availability of the funds for further research and studies in an effort to safety and efficacy of Inovio's technology as a delivery mechanism, the availability or potential availability of alternative therapies or treatments for the conditions of Inovio or its staff, including alternatives that may be more effective or more cost-effective than any therapy or treatment, hoping that Inovio and its employees to develop targeted, evaluation of potential opportunities, issues relating to patents and whether they or licenses to them Inovio with meaningful protection from others about the hidden technologies offer, whether such proprietary rights are enforceable or defend or violating or allegedly on rights of others are injured or can withstand claims of invalidity and whether fund Inovio can or devote other significant resources that are required to keep track of, to protect or defend, to the level of corporate expenditures, assessments of our technology by potential corporate or other partners or collaborators, capital market conditions, and other factors discussed in our Annual Report form 10-K for the year ending 31 December 2007 set, our 10-Q for the three months ended 31st March 2008, and other regulatory filings from time to time.####from the study was scholars by of Academy of Sciences in the Czech Republic , the Institute for Clinical and Experimental Medicine , Osaka University Graduate School of Medicine , in Sapporo medicalpicture University , University of California, in San Francisco, and University of Michigan Medical School in.

Using the product:-:, Pravenec, Hyakukoku the manuscript line ahead of print released his full quotation reads as follows Houstek, Zidek V.6548207.